cancer vaccines pipeline insight

DelveInsight’s, “Cancer Vaccines - Pipeline Insight, 2026” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Cancer Vaccines pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cancer Vaccines: Understanding

Cancer Vaccines: Overview

Cancer Vaccines are therapeutic or preventive immunotherapies designed to stimulate the body’s immune system to recognize and attack cancer-specific antigens. The advent of cancer immunotherapy has revolutionized the field of cancer treatment and offers cancer patients new hope. Although this therapy has proved highly successful for some patients, its efficacy is not all encompassing and several cancer types do not respond. Cancer vaccines offer an alternate approach to promote anti-tumor immunity that differ in their mode of action from antibody-based therapies. Cancer vaccines serve to balance the equilibrium of the crosstalk between the tumor cells and the host immune system.

 

While a large number of strategies have been developed for the preparation and formulation of cancer vaccines (whole cell-, peptide- or nucleotide-based), it still remains challenging to develop an effective common delivery platform for these vaccines that would stimulate potent anti-tumor immune responses. To date, several vaccine delivery strategies have been developed that are currently in preclinical or clinical studies, including bacterial and viral vector-based strategies, DC-based delivery strategies and biomaterial-based delivery systems, each with their pros and cons.

 

Cancer vaccines can either be prophylactic (preventative) or therapeutic (curative). An exciting option for therapeutic vaccines is the emergence of personalized vaccines, which are tailor-made and specific for tumor type and individual patient. Prophylactic vaccines are designed to prevent a cancer from establishing itself and have proven to be successful in reducing the global burden associated with two cancer-causing viruses, Hepatitis B Virus (HBV) and Human Papilloma Virus (HPV). Therapeutic cancer vaccines have been tested in the clinic for several decades. Several different categories of therapeutic cancer vaccines are currently being evaluated. These include cellular (whole tumor/immune cells), viral vector, or molecular (peptide, TAA-encoding DNA, or RNA). The therapeutic efficacy of these agents has been improved by using the optimal formulation for vaccine delivery and by co-administration of immunological adjuvants, immune stimulatory cytokines and addition of costimulatory molecules.

 

Given the existence of such diverse vaccine platforms that potentially engage the innate and adaptive immune components, it is feasible and attractive to use combinatorial cancer vaccine therapy. In addition to cancer vaccines, a wide range of other promising immunotherapeutic modalities is being tested or approved for cancer treatment. These include adoptive cell transfer of ex vivo expanded tumor infiltrating lymphocytes, use of therapeutic antibodies (e.g., trastuzumab) for antagonizing oncogenic pathways and triggering antibody dependent cytotoxicity and phagocytosis, and administration of immune modulating antibodies targeting both co-inhibitory and co-stimulatory receptors on activated T cells or the corresponding ligands on APCs as well as tumor cells to enhance antitumor immune responses.

 

"Cancer Vaccines- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cancer Vaccines pipeline landscape is provided which includes the disease overview and Cancer Vaccines treatment guidelines. The assessment part of the report embraces, in depth Cancer Vaccines commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cancer Vaccines collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cancer Vaccines R&D. The therapies under development are focused on novel approaches to treat/improve Cancer Vaccines.

Cancer Vaccines Emerging Drugs Chapters

This segment of the Cancer Vaccines report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cancer Vaccines Emerging Drugs

Intismeran autogene: Moderna Therapeutics/Merck

Intismeran autogene (mRNA-4157) is a novel investigational messenger RNA (mRNA)-based individualized neoantigen therapy (INT) consisting of a synthetic mRNA coding for up to 34 neoantigens that is designed and produced based on the unique mutational signature of the DNA sequence of the patient’s tumor. Upon administration into the body, the algorithmically derived and RNA-encoded neoantigen sequences are endogenously translated and undergo natural cellular antigen processing and presentation, a key step in adaptive immunity. Individualized neoantigen therapies are designed to train and activate an antitumor immune response by generating specific T-cell responses based on the unique mutational signature of a patient’s tumor. The drug is in Phase III stage for the development of Melanoma and Non-small cell lung cancer.

 

EO2401: Enterome

EO2401 is an off-the-shelf, peptide-based therapeutic cancer vaccine developed by Enterome using its OncoMimics™ platform. The vaccine comprises three microbiome-derived peptides designed to mimic tumor-associated antigens (TAAs) IL13Ra2, BIRC5/survivin, and FOXM1, along with the CD4+ helper peptide UCP2. By exploiting molecular mimicry between bacterial peptides and tumor antigens, EO2401 is designed to activate pre-existing memory CD8+ T cells that recognize the microbial peptides and cross-react with the corresponding tumor antigens, thereby generating a targeted cytotoxic immune response against cancer cells. The therapy is being evaluated in Phase II clinical trials for recurrent glioblastoma.

 

TG4050: Transgene/NEC Corporation

TG4050 is an individualized neoantigen therapeutic cancer vaccine developed by Transgene in collaboration with NEC Corporation. It is based on Transgene’s myvac® viral-vector platform and uses NEC’s AI- and machine-learning–based Neoantigen Prediction System to identify and prioritize tumor-specific mutations (neoantigens) from each patient’s tumor. TG4050 is individually manufactured for each patient and encodes up to 30 selected neoantigens, with the aim of stimulating a tumor-specific T-cell response, particularly CD8+ T cells, capable of recognizing and destroying cancer cells carrying those neoantigens. Currently, the drug is in being evaluated in Phase II stage of its development for the treatment of Squamous Cell Carcinoma of Head and Neck. TG4050 is being evaluated in a randomized multicenter Phase II part of a Phase I/II trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers (HNSCC).

 

ELI-002: Elicio Therapeutics

ELI-002 is a structurally novel investigational AMP cancer immunotherapy that targets cancers that are driven by mutations in the KRAS-gene which is a prevalent driver of many human cancers. ELI-002 is comprised of two powerful components that are built with Elicio’s proprietary AMP technology consisting of AMP-modified mutant KRAS peptide antigens and ELI-004, an AMP-modified CpG oligodeoxynucleotide adjuvant that is available as an off-the-shelf subcutaneous administration. Currently, the drug is in being evaluated in Phase I/II stage of its development for the treatment of pancreatic cancer.

 

IRZ-03: Irazu Oncology

IRZ-03 is an off-the-shelf, outer membrane vesicle (OMV)-based cancer immunotherapy being developed by Irazú Oncology for checkpoint inhibitor–refractory solid tumors, including colorectal, non-small cell lung, gastric, pancreatic, and head and neck cancers. The candidate is designed to function as a therapeutic cancer vaccine by directing the immune system against the tumor-associated antigens CEA (CEACAM5) and MUC1, while simultaneously targeting PD-L1–expressing immunosuppressive cells within the tumor microenvironment. Irazú states that IRZ-03 is engineered to generate coordinated T-cell and B-cell responses against CEA and MUC1, eliminate PD-L1-positive immunosuppressive myeloid and dendritic-cell populations, and establish durable immune memory. Currently, the drug is in being evaluated in Preclinical stage of its development for the treatment of Squamous Cell Carcinoma of Head and Neck.

Further product details are provided in the report……..

Cancer Vaccines: Therapeutic Assessment

This segment of the report provides insights about the different Cancer Vaccines drugs segregated based on following parameters that define the scope of the report, such as:

 

Major Players in Cancer Vaccines

There are approx. 200+ key companies which are developing the therapies Cancer Vaccines. The companies which have their Cancer Vaccines drug candidates in the most advanced stage, i.e. Phase III include, Intismeran autogene, and others.

 

Phases

DelveInsight’s report covers around 200+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Cancer Vaccines pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

 

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cancer Vaccines: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cancer Vaccines therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cancer Vaccines drugs.

Cancer Vaccines Report Insights

• Cancer Vaccines Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cancer Vaccines Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cancer Vaccines drugs?
• How many Cancer Vaccines drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cancer Vaccines?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cancer Vaccines therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cancer Vaccines and their status?
• What are the key designations that have been granted to the emerging drugs?